Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER
10% OFF

Update : discount is suspended
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

London TMAU meeting with Prof Liz Shephard
19th Oct 11am - 1pm
St Mary's Hospital
Praed St, Paddington
London W2 1NY
click to read more

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Sunday, February 10, 2013

5th TMAU webinar : Fennessey - Preti - Reed



5th TMAU webinar provided by Rob Pleticha and rareconnect.org See additional answers to questions on the RareConnect site.

Paul Fennessey PhD :  Recognition of TMAU as disease entity and development of choline challenge test
George Preti PhD : Evaluation of individuals with malodor problems
Danielle Reed PhD : Genetics of TMAU

Our thank you goes to Drs. Reed, Fennessey, and Preti for their informative presentation. Since there wasn't enough time for all the questions to be answered, and since they requested that viewers submit questions for them to answer, we have copied and pasted the Q & A posted at this time in RareConnect. Thanks to all guests who also participated in asking very valuable questions.

Questions and Answers that we did not have time for during the webinar

  • Mar-----: Ok, my understanding of the methylation process is when some compounds receive a methyl group, this "starts" a reaction (such as turning a gene on or activating an enzyme). When the methyl group is "lost" or removed, the reaction stops (or a gene is turned off or the enzyme is deactivated). With this in mind, couldn’t it be possible, by having a specific methylation problem, the enzyme may be deactivated, thereby causing a lack of ability to metabolize TMA?
  • Dr. Reed: It is possible that the genomic DNA which codes for FMO3 could be blocked from transcription by either DNA methylation dynamics or through modificaiton to histones - or it could be that transcription factors which initiate FMO3 transcription are lacking in some patients. Right now there is no quick test to assess human FMO3 genomic methylation because it requires liver biopsy.

link to RareConnect site where additional Q&As may be noted.

0 comments:

Post a Comment